Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therap...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 385; no. 12; pp. 1091 - 1103
Main Authors Sartor, Oliver, de Bono, Johann, Chi, Kim N, Fizazi, Karim, Herrmann, Ken, Rahbar, Kambiz, Tagawa, Scott T, Nordquist, Luke T, Vaishampayan, Nitin, El-Haddad, Ghassan, Park, Chandler H, Beer, Tomasz M, Armour, Alison, Pérez-Contreras, Wendy J, DeSilvio, Michelle, Kpamegan, Euloge, Gericke, Germo, Messmann, Richard A, Morris, Michael J, Krause, Bernd J
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 16.09.2021
Subjects
Adverse events
Aged
Aged, 80 and over
Androgen receptors
Androgens
Antigens
Biomarkers
Cancer therapies
Castration
Chemotherapy
Combined Modality Therapy
Computed tomography
Dipeptides - therapeutic use
Disease control
Drug dosages
Drug withdrawal
FDA approval
Gallium
Hematology
Heterocyclic Compounds, 1-Ring - therapeutic use
Humans
Immunotherapy
Kallikreins - antagonists & inhibitors
Lutetium - adverse effects
Lutetium - therapeutic use
Magnetic resonance imaging
Male
Medical prognosis
Metastases
Metastasis
Microenvironments
Middle Aged
Oncology
Pain
Patients
Positron-Emission Tomography
Prostate - diagnostic imaging
Prostate cancer
Prostate Disease
Prostate Disease General
Prostate-Specific Antigen - antagonists & inhibitors
Prostate-Specific Antigen - therapeutic use
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Prostatic Neoplasms, Castration-Resistant - radiotherapy
Quality of life
Radiation
Radioisotopes - adverse effects
Radioisotopes - therapeutic use
Radium
Survival Analysis
Treatments in Oncology
Urology
Online AccessGet full text

Cover

Abstract Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therapy prolonged progression-free and overall survival. Adverse effects were more common, but quality of life was maintained.
AbstractList AbstractBackgroundMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.MethodsWe conducted an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor–pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)–labeled PSMA-11 positron-emission tomographic–computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. Protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 (223Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment.ResultsFrom June 2018 to mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. 177Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001) and overall survival (median, 15.3 vs. 11.3 months; hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001). All the key secondary end points significantly favored 177Lu-PSMA-617. The incidence of adverse events of grade 3 or above was higher with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.ConclusionsRadioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.)
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.BACKGROUNDMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.We conducted an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)-labeled PSMA-11 positron-emission tomographic-computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. Protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 (223Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment.METHODSWe conducted an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 (68Ga)-labeled PSMA-11 positron-emission tomographic-computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either 177Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. Protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 (223Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment.From June 2018 to mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. 177Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001) and overall survival (median, 15.3 vs. 11.3 months; hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001). All the key secondary end points significantly favored 177Lu-PSMA-617. The incidence of adverse events of grade 3 or above was higher with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.RESULTSFrom June 2018 to mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. 177Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001) and overall survival (median, 15.3 vs. 11.3 months; hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001). All the key secondary end points significantly favored 177Lu-PSMA-617. The incidence of adverse events of grade 3 or above was higher with 177Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected.Radioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).CONCLUSIONSRadioligand therapy with 177Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).
Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therapy prolonged progression-free and overall survival. Adverse effects were more common, but quality of life was maintained.
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 ( Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. We conducted an international, open-label, phase 3 trial evaluating Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens and who had PSMA-positive gallium-68 ( Ga)-labeled PSMA-11 positron-emission tomographic-computed tomographic scans. Patients were randomly assigned in a 2:1 ratio to receive either Lu-PSMA-617 (7.4 GBq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. Protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 ( Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment. From June 2018 to mid-October 2019, a total of 831 of 1179 screened patients underwent randomization. The baseline characteristics of the patients were balanced between the groups. The median follow-up was 20.9 months. Lu-PSMA-617 plus standard care significantly prolonged, as compared with standard care, both imaging-based progression-free survival (median, 8.7 vs. 3.4 months; hazard ratio for progression or death, 0.40; 99.2% confidence interval [CI], 0.29 to 0.57; P<0.001) and overall survival (median, 15.3 vs. 11.3 months; hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001). All the key secondary end points significantly favored Lu-PSMA-617. The incidence of adverse events of grade 3 or above was higher with Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected. Radioligand therapy with Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).
Author Herrmann, Ken
Gericke, Germo
Morris, Michael J
Krause, Bernd J
Chi, Kim N
Nordquist, Luke T
DeSilvio, Michelle
Kpamegan, Euloge
Fizazi, Karim
El-Haddad, Ghassan
Park, Chandler H
Vaishampayan, Nitin
de Bono, Johann
Tagawa, Scott T
Armour, Alison
Messmann, Richard A
Pérez-Contreras, Wendy J
Sartor, Oliver
Beer, Tomasz M
Rahbar, Kambiz
Author_xml – sequence: 1
  givenname: Oliver
  orcidid: 0000-0002-8777-7343
  surname: Sartor
  fullname: Sartor, Oliver
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 2
  givenname: Johann
  surname: de Bono
  fullname: de Bono, Johann
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 3
  givenname: Kim N
  surname: Chi
  fullname: Chi, Kim N
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 4
  givenname: Karim
  surname: Fizazi
  fullname: Fizazi, Karim
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 5
  givenname: Ken
  surname: Herrmann
  fullname: Herrmann, Ken
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 6
  givenname: Kambiz
  surname: Rahbar
  fullname: Rahbar, Kambiz
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 7
  givenname: Scott T
  surname: Tagawa
  fullname: Tagawa, Scott T
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 8
  givenname: Luke T
  surname: Nordquist
  fullname: Nordquist, Luke T
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 9
  givenname: Nitin
  surname: Vaishampayan
  fullname: Vaishampayan, Nitin
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 10
  givenname: Ghassan
  surname: El-Haddad
  fullname: El-Haddad, Ghassan
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 11
  givenname: Chandler H
  surname: Park
  fullname: Park, Chandler H
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 12
  givenname: Tomasz M
  surname: Beer
  fullname: Beer, Tomasz M
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 13
  givenname: Alison
  surname: Armour
  fullname: Armour, Alison
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 14
  givenname: Wendy J
  surname: Pérez-Contreras
  fullname: Pérez-Contreras, Wendy J
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 15
  givenname: Michelle
  surname: DeSilvio
  fullname: DeSilvio, Michelle
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 16
  givenname: Euloge
  surname: Kpamegan
  fullname: Kpamegan, Euloge
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 17
  givenname: Germo
  surname: Gericke
  fullname: Gericke, Germo
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 18
  givenname: Richard A
  surname: Messmann
  fullname: Messmann, Richard A
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 19
  givenname: Michael J
  surname: Morris
  fullname: Morris, Michael J
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
– sequence: 20
  givenname: Bernd J
  surname: Krause
  fullname: Krause, Bernd J
  organization: From the School of Medicine, Tulane University, New Orleans (O.S.); the Institute of Cancer Research and Royal Marsden Hospital, London (J.B.); the British Columbia Cancer Agency, Vancouver, Canada (K.N.C.); Gustave Roussy Institute, Paris-Saclay University, Villejuif, France (K.F.); the University of Duisberg–Essen and German Cancer Consortium, University Hospital Essen, Essen (K.H.), University Hospital Münster, Münster (K.R.), and Rostock University Medical Center, Rostock (B.J.K.) — all in Germany; Weill Cornell Medicine (S.T.T.) and Memorial Sloan Kettering Cancer Center (M.J.M.) — both in New York; the Urology Cancer Center, Omaha, NE (L.T.N.); the School of Medicine, Wayne State University, Detroit (N.V.); Moffitt Cancer Center and Research Institute, Tampa, FL (G.E.-H.); Norton Cancer Institute, Louisville, KY (C.H.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (T.M.B.); Endocyte (a Novartis company), West Lafayette, IN (A.A.); Novartis Pharmaceuticals, East Hanover, NJ (W.J.P.-C., M.D., E.K., R.A.M.); and Novartis Pharma, Basel, Switzerland (G.G.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34161051$$D View this record in MEDLINE/PubMed
BookMark eNpdkMlOwzAQhi0EogscuaJICIlLwFvs-FhVZW2hYjlbTjKVUtV2iZMDN96BN-RJcNVygLnMaOabmV__AO077wChE4IvCc7E1ePkfuYNJVgySvdQn2SMpZxjsY_6GNM85VKxHhqEsMQxCFeHqMc4EXGb9NHDtGuhrTubEim_P7_mL7NRKohMFr5JZtCa0Jq2LpNxLJpYeZc-Q6hj17XJvPGbMcSpK6E5QgcLswpwvMtD9HY9eR3fptOnm7vxaJpaKlQbHzEpVV4RChkrFC0Ui_pLYQg1FWBB-IIKnJelkVDhouAZYAwytgpGq6xgQ3Sxvbtu_HsHodW2DiWsVsaB74KmGec8UxTnET37hy5917ioLlKSKknz6NcQne6orrBQ6XVTW9N86F-bInC-BawN2sHSaoL1xn79x372A6NrdHA
ContentType Journal Article
Contributor Emmenegger, Urban
Krause, Bernd Joachim
Laidley, David
Liu, Frank
Shore, Neal
Shah, Satish
Morris, Michael
Payne, Heather
Franklin, Gregg
Guix, Carlos Artigas
Bubley, Glenn
Molina-Vicenty, Irma
Babiker, Hani
Reza Berenji, Gholam
Tutrone, Jr, Ronald
Buus, Simon
Sartor, Oliver
Czernin, Johannes
Elliott, David
Ferrario, Cristiano
Bahl, Amit
Mahammedi, Hakim
Michalski, Jeff
Nagarajah, James
Fizazi, Karim
Delpassand, Ebrahim
Nordquist, Luke
Chi, Kim
Saad, Fred
Vaishampayan, Nitin
de Bono, Johann
Koshkin, Vadim
Kendi, Ayse
Park, Chandler
Lavalaye, Jules
Pinho, Daniella
Widmark, Anders
Sundlov, Anna
Jones, Robert
Beauregard, Jean-Mathieu
Cazeau, Anne
Vogelzang, Nicholas
Beer, Tomasz
El-Haddad, Ghassan
Farukhi, Irfan
Hussain, Arif
Kempel, Mette Moe
Gauthe, Mathieu
Tagawa, Scott
Crabb, Simon
Osman, Medhat
Den, Robert
Armstrong, Andrew
Ong, Michael
Janssen, Marcel
Beuselinck, Benoit
Fang, Bruno
Srinivas, Sandhya
Chang, Brian
Bane, Charles
Rahbar, Kambiz
Adra, Nabil
Herrmann, Ken
Enting, Deborah
Zhao, Song
Garje, Rohan
Dreicer, Robert
Vogel, Wouter
Wei, Xiao
Johan
Contributor_xml – sequence: 1
  givenname: Carlos Artigas
  surname: Guix
  fullname: Guix, Carlos Artigas
– sequence: 2
  givenname: Benoit
  surname: Beuselinck
  fullname: Beuselinck, Benoit
– sequence: 3
  givenname: Renaud
  surname: Lhommel
  fullname: Lhommel, Renaud
– sequence: 4
  givenname: Jean-Mathieu
  surname: Beauregard
  fullname: Beauregard, Jean-Mathieu
– sequence: 5
  givenname: Kim
  surname: Chi
  fullname: Chi, Kim
– sequence: 6
  givenname: Urban
  surname: Emmenegger
  fullname: Emmenegger, Urban
– sequence: 7
  givenname: Cristiano
  surname: Ferrario
  fullname: Ferrario, Cristiano
– sequence: 8
  givenname: David
  surname: Laidley
  fullname: Laidley, David
– sequence: 9
  givenname: Michael
  surname: Ong
  fullname: Ong, Michael
– sequence: 10
  givenname: Fred
  surname: Saad
  fullname: Saad, Fred
– sequence: 11
  givenname: Simon
  surname: Buus
  fullname: Buus, Simon
– sequence: 12
  givenname: Mette Moe
  surname: Kempel
  fullname: Kempel, Mette Moe
– sequence: 13
  givenname: Peter
  surname: Petersen
  fullname: Petersen, Peter
– sequence: 14
  givenname: Anne
  surname: Cazeau
  fullname: Cazeau, Anne
– sequence: 15
  givenname: Frederic
  surname: Courbon
  fullname: Courbon, Frederic
– sequence: 16
  givenname: Karim
  surname: Fizazi
  fullname: Fizazi, Karim
– sequence: 17
  givenname: Aude
  surname: Flechon
  fullname: Flechon, Aude
– sequence: 18
  givenname: Mathieu
  surname: Gauthe
  fullname: Gauthe, Mathieu
– sequence: 19
  givenname: Hakim
  surname: Mahammedi
  fullname: Mahammedi, Hakim
– sequence: 20
  givenname: Matthias
  surname: Eiber
  fullname: Eiber, Matthias
– sequence: 21
  givenname: Ken
  surname: Herrmann
  fullname: Herrmann, Ken
– sequence: 22
  givenname: Bernd Joachim
  surname: Krause
  fullname: Krause, Bernd Joachim
– sequence: 23
  givenname: Kambiz
  surname: Rahbar
  fullname: Rahbar, Kambiz
– sequence: 24
  givenname: Bart de
  surname: Keizer
  fullname: Keizer, Bart de
– sequence: 25
  givenname: Marcel
  surname: Janssen
  fullname: Janssen, Marcel
– sequence: 26
  givenname: Jules
  surname: Lavalaye
  fullname: Lavalaye, Jules
– sequence: 27
  givenname: James
  surname: Nagarajah
  fullname: Nagarajah, James
– sequence: 28
  givenname: Wouter
  surname: Vogel
  fullname: Vogel, Wouter
– sequence: 29
  givenname: Irma
  surname: Molina-Vicenty
  fullname: Molina-Vicenty, Irma
– sequence: 30
  givenname: Enrique
  surname: Castellanos
  fullname: Castellanos, Enrique
– sequence: 31
  givenname: Silvia
  surname: Johansson
  fullname: Johansson, Silvia
– sequence: 32
  givenname: Jon
  surname: Kindblom
  fullname: Kindblom, Jon
– sequence: 33
  givenname: Anna
  surname: Sundlov
  fullname: Sundlov, Anna
– sequence: 34
  givenname: Anders
  surname: Widmark
  fullname: Widmark, Anders
– sequence: 35
  givenname: Amit
  surname: Bahl
  fullname: Bahl, Amit
– sequence: 36
  givenname: Simon
  surname: Crabb
  fullname: Crabb, Simon
– sequence: 37
  givenname: Johann
  surname: de Bono
  fullname: de Bono, Johann
– sequence: 38
  givenname: Deborah
  surname: Enting
  fullname: Enting, Deborah
– sequence: 39
  givenname: Robert
  surname: Jones
  fullname: Jones, Robert
– sequence: 40
  givenname: Heather
  surname: Payne
  fullname: Payne, Heather
– sequence: 41
  givenname: Carla
  surname: Perna
  fullname: Perna, Carla
– sequence: 42
  givenname: Nabil
  surname: Adra
  fullname: Adra, Nabil
– sequence: 43
  givenname: Andrew
  surname: Armstrong
  fullname: Armstrong, Andrew
– sequence: 44
  givenname: Hani
  surname: Babiker
  fullname: Babiker, Hani
– sequence: 45
  givenname: Charles
  surname: Bane
  fullname: Bane, Charles
– sequence: 46
  givenname: Tomasz
  surname: Beer
  fullname: Beer, Tomasz
– sequence: 47
  givenname: Gholam
  surname: Reza Berenji
  fullname: Reza Berenji, Gholam
– sequence: 48
  givenname: Glenn
  surname: Bubley
  fullname: Bubley, Glenn
– sequence: 49
  givenname: Brian
  surname: Chang
  fullname: Chang, Brian
– sequence: 50
  givenname: Bennett
  surname: Chin
  fullname: Chin, Bennett
– sequence: 51
  givenname: Johannes
  surname: Czernin
  fullname: Czernin, Johannes
– sequence: 52
  givenname: Ebrahim
  surname: Delpassand
  fullname: Delpassand, Ebrahim
– sequence: 53
  givenname: Robert
  surname: Den
  fullname: Den, Robert
– sequence: 54
  givenname: Robert
  surname: Dreicer
  fullname: Dreicer, Robert
– sequence: 55
  givenname: Ghassan
  surname: El-Haddad
  fullname: El-Haddad, Ghassan
– sequence: 56
  givenname: David
  surname: Elliott
  fullname: Elliott, David
– sequence: 57
  givenname: Bruno
  surname: Fang
  fullname: Fang, Bruno
– sequence: 58
  givenname: Irfan
  surname: Farukhi
  fullname: Farukhi, Irfan
– sequence: 59
  givenname: Gregg
  surname: Franklin
  fullname: Franklin, Gregg
– sequence: 60
  givenname: Rohan
  surname: Garje
  fullname: Garje, Rohan
– sequence: 61
  givenname: Michael
  surname: Gordon
  fullname: Gordon, Michael
– sequence: 62
  givenname: Arif
  surname: Hussain
  fullname: Hussain, Arif
– sequence: 63
  givenname: Ayse
  surname: Kendi
  fullname: Kendi, Ayse
– sequence: 64
  givenname: Vadim
  surname: Koshkin
  fullname: Koshkin, Vadim
– sequence: 65
  givenname: Frank
  surname: Liu
  fullname: Liu, Frank
– sequence: 66
  givenname: Jeff
  surname: Michalski
  fullname: Michalski, Jeff
– sequence: 67
  givenname: Alicia
  surname: Morgans
  fullname: Morgans, Alicia
– sequence: 68
  givenname: Michael
  surname: Morris
  fullname: Morris, Michael
– sequence: 69
  givenname: Luke
  surname: Nordquist
  fullname: Nordquist, Luke
– sequence: 70
  givenname: Medhat
  surname: Osman
  fullname: Osman, Medhat
– sequence: 71
  givenname: Chandler
  surname: Park
  fullname: Park, Chandler
– sequence: 72
  givenname: Daniel
  surname: Petrylak
  fullname: Petrylak, Daniel
– sequence: 73
  givenname: Morand
  surname: Piert
  fullname: Piert, Morand
– sequence: 74
  givenname: Daniella
  surname: Pinho
  fullname: Pinho, Daniella
– sequence: 75
  givenname: Oliver
  surname: Sartor
  fullname: Sartor, Oliver
– sequence: 76
  givenname: Satish
  surname: Shah
  fullname: Shah, Satish
– sequence: 77
  givenname: Neal
  surname: Shore
  fullname: Shore, Neal
– sequence: 78
  givenname: Sandhya
  surname: Srinivas
  fullname: Srinivas, Sandhya
– sequence: 79
  givenname: Scott
  surname: Tagawa
  fullname: Tagawa, Scott
– sequence: 80
  givenname: Ronald
  surname: Tutrone, Jr
  fullname: Tutrone, Jr, Ronald
– sequence: 81
  givenname: Nitin
  surname: Vaishampayan
  fullname: Vaishampayan, Nitin
– sequence: 82
  givenname: Nicholas
  surname: Vogelzang
  fullname: Vogelzang, Nicholas
– sequence: 83
  givenname: Xiao
  surname: Wei
  fullname: Wei, Xiao
– sequence: 84
  givenname: Song
  surname: Zhao
  fullname: Zhao, Song
Copyright Copyright © 2021 Massachusetts Medical Society. All rights reserved.
Copyright © 2021 Massachusetts Medical Society.
Copyright_xml – notice: Copyright © 2021 Massachusetts Medical Society. All rights reserved.
– notice: Copyright © 2021 Massachusetts Medical Society.
CorporateAuthor VISION Investigators
CorporateAuthor_xml – name: VISION Investigators
DBID CGR
CUY
CVF
ECM
EIF
NPM
7RV
7X7
7XB
8AO
8C1
8FE
8FH
8FI
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BEC
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K0Y
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
DOI 10.1056/NEJMoa2107322
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Nursing & Allied Health Database
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
eLibrary
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
New England Journal of Medicine
ProQuest Biological Science Collection
Consumer Health Database
Healthcare Administration Database
Medical Database
Psychology Database
Research Library
Science Database
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
elibrary
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
New England Journal of Medicine
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList ProQuest One Psychology
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-4406
EndPage 1103
ExternalDocumentID 34161051
NJ202109163851207
Genre Original Article
Clinical Trial, Phase III
Multicenter Study
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation Endocyte, Inc., a Novartis Company
Advanced Accelerator Applications, a Novartis company
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA022453
– fundername: NCI NIH HHS
  grantid: P30 CA008748
GroupedDBID -
0R
0WA
123
1VV
29N
2KS
2WC
34G
39C
4
4.4
53G
55
5RE
7FN
7RV
7X7
85S
8AO
8C1
8FE
8FH
8FI
9M8
AACLI
AAEJM
AAIKC
AALRV
AAPBV
AAQQT
AARDX
AAUTI
AAWTL
ABACO
ABEHJ
ABFLS
ABIVO
ABOCM
ABPPZ
ABPTK
ABQIJ
ABUWG
ABWJO
ACGFS
ACGOD
ACJLH
ACNCT
ACPRK
ACPVT
ACRZS
ADBBV
ADBIT
ADCBC
AENEX
AETEA
AFFNX
AFHKK
AFKRA
AGFXO
AGNAY
AHMBA
AJJEV
AJVPN
ALMA_UNASSIGNED_HOLDINGS
AN0
AQUVI
AZQEC
BBAFP
BBNVY
BCU
BENPR
BES
BHPHI
BKEYQ
BKNYI
BLC
BNQBC
BPHCQ
BVXVI
C45
CJ0
CO
CS3
DCD
DU5
DWQXO
DZ
EBS
ET
EX3
F5P
FD8
FM.
FYUFA
GJ
GNUQQ
GUQSH
HCIFZ
HZ
I4R
IH2
K-O
KM
KOO
L7B
LK8
M0R
M0T
M1P
M2M
M2O
M2P
M7P
MQT
MVM
N9A
NAPCQ
NEJ
O9-
OK1
OMK
OVD
P-O
P-S
P2P
PADUT
PCD
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
QJJ
RHI
RWL
RXW
S10
S6N
SJFOW
SJN
TAE
TAF
TEORI
TN5
TWZ
UCV
UKR
UMD
VQA
W2G
WH7
WOQ
WOW
X
X7M
XJT
XYN
XZL
YCJ
YNT
YRY
YZZ
ZA5
ZHY
ZR0
---
-DZ
-ET
-~X
.-4
.55
.CO
.GJ
0R~
36B
AAMNW
ABBLC
ABCQX
ABDQB
ABJNI
ACKOT
ACPFK
ADRHT
ADUKH
AERZD
AFOSN
AGHSJ
ALIPV
BYPQX
CCPQU
CGR
CUY
CVF
ECM
EIF
HF~
HMCUK
HZ~
N4W
NPM
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PSYQQ
TUQ
UKHRP
YFH
YR2
YR5
YYP
ZCA
ZVN
~KM
7XB
BEC
K0Y
MBDVC
PKEHL
PUEGO
Q9U
7X8
ID FETCH-LOGICAL-m269t-1737798d12e53b92b93a21c6a12ade0614f2608cca7ed0bb45e00e7608b32d5b3
IEDL.DBID 7X7
ISSN 0028-4793
1533-4406
IngestDate Fri Jul 11 15:36:00 EDT 2025
Sat Aug 23 14:58:11 EDT 2025
Mon Jul 21 05:51:27 EDT 2025
Tue Dec 21 14:38:53 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
License Copyright © 2021 Massachusetts Medical Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-m269t-1737798d12e53b92b93a21c6a12ade0614f2608cca7ed0bb45e00e7608b32d5b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-8777-7343
PMID 34161051
PQID 2572972853
PQPubID 40644
PageCount 13
ParticipantIDs proquest_miscellaneous_2544459208
proquest_journals_2572972853
pubmed_primary_34161051
mms_nejm_10_1056_NEJMoa2107322
PublicationCentury 2000
PublicationDate 20210916
2021-09-16
PublicationDateYYYYMMDD 2021-09-16
PublicationDate_xml – month: 09
  year: 2021
  text: 20210916
  day: 16
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Boston
PublicationTitle The New England journal of medicine
PublicationTitleAlternate N Engl J Med
PublicationYear 2021
Publisher Massachusetts Medical Society
Publisher_xml – name: Massachusetts Medical Society
References Violet, J, Sandhu, S, Iravani, A (r24) 2020; 61
Yadav, MP, Ballal, S, Sahoo, RK, Dwivedi, SN, Bal, C (r20) 2019; 213
Rahbar, K, Ahmadzadehfar, H, Kratochwil, C (r19) 2017; 58
Horoszewicz, JS, Kawinski, E, Murphy, GP (r9) 1987; 7
Minner, S, Wittmer, C, Graefen, M (r12) 2011; 71
Hupe, MC, Philippi, C, Roth, D (r10) 2018; 8
Antonarakis, ES, Piulats, JM, Gross-Goupil, M (r5) 2020; 38
Nuhn, P, De Bono, JS, Fizazi, K (r2) 2019; 75
Bostwick, DG, Pacelli, A, Blute, M, Roche, P, Murphy, GP (r11) 1998; 82
Hofman, MS, Violet, J, Hicks, RJ (r23) 2018; 19
Sweat, SD, Pacelli, A, Murphy, GP, Bostwick, DG (r13) 1998; 52
von Eyben, FE, Roviello, G, Kiljunen, T (r22) 2018; 45
Eisenhauer, EA, Therasse, P, Bogaerts, J (r31) 2009; 45
Israeli, RS, Powell, CT, Fair, WR, Heston, WD (r8) 1993; 53
Paschalis, A, Sheehan, B, Riisnaes, R (r14) 2019; 76
Kim, YJ, Kim, Y-I (r21) 2018; 43
Afshar-Oromieh, A, Hetzheim, H, Kratochwil, C (r16) 2015; 56
Abida, W, Patnaik, A, Campbell, D (r6) 2020; 38
Parker, C, Nilsson, S, Heinrich, D (r30) 2013; 369
Sartor, O, de Bono, JS (r1) 2018; 378
Rowe, SP, Gorin, MA, Pomper, MG (r7) 2019; 70
Vlachostergios, PJ, Niaz, MJ, Sun, M (r15) 2021; 11
Hofman, MS, Emmett, L, Sandhu, S (r25) 2021; 397
Fendler, WP, Eiber, M, Beheshti, M (r27) 2017; 44
de Bono, J, Mateo, J, Fizazi, K (r3) 2020; 382
Banerjee, S, Pillai, MRA, Knapp, FFR (r18) 2015; 115
Hussain, M, Mateo, J, Fizazi, K (r4) 2020; 383
Scher, HI, Morris, MJ, Stadler, WM (r29) 2016; 34
Oken, MM, Creech, RH, Tormey, DC (r28) 1982; 5
Hochberg, Y, Tamhane, A (r32) 1987
Lu, K, Li, D, Koch, GG (r33) 2015; 7
Violet, J, Jackson, P, Ferdinandus, J (r17) 2019; 60
Rahbar, K, Bodei, L, Morris, MJ (r26) 2019; 60
Atkinson, A, Kenward, MG, Clayton, T, Carpenter, JR (r34) 2019; 18
34262157 - Nat Rev Clin Oncol. 2021 Sep;18(9):542
34784728 - J Urol. 2022 Feb;207(2):467-469
34312019 - Eur Urol. 2021 Oct;80(4):520-521
34936751 - N Engl J Med. 2021 Dec 23;385(26):2494
34825836 - Radiol Imaging Cancer. 2021 Nov;3(6):e219026
37032186 - Eur Urol. 2023 Jul;84(1):7-8
34936753 - N Engl J Med. 2021 Dec 23;385(26):2495
34331044 - Nat Rev Urol. 2021 Sep;18(9):510
34936752 - N Engl J Med. 2021 Dec 23;385(26):2494-2495
References_xml – volume: 60
  start-page: 1504
  year: 2019
  end-page: 1506
  ident: r26
  article-title: Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics.
  publication-title: J Nucl Med
– volume: 7
  start-page: 927
  year: 1987
  end-page: 935
  ident: r9
  article-title: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
  publication-title: Anticancer Res
– volume: 397
  start-page: 797
  year: 2021
  end-page: 804
  ident: r25
  article-title: [ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
  publication-title: Lancet
– volume: 383
  start-page: 2345
  year: 2020
  end-page: 2357
  ident: r4
  article-title: Survival with olaparib in metastatic castration-resistant prostate cancer.
  publication-title: N Engl J Med
– volume: 8
  start-page: 623
  year: 2018
  end-page: 623
  ident: r10
  article-title: Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis.
  publication-title: Front Oncol
– volume: 52
  start-page: 637
  year: 1998
  end-page: 640
  ident: r13
  article-title: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
  publication-title: Urology
– volume: 43
  start-page: 728
  year: 2018
  end-page: 734
  ident: r21
  article-title: Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis.
  publication-title: Clin Nucl Med
– volume: 369
  start-page: 213
  year: 2013
  end-page: 223
  ident: r30
  article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer.
  publication-title: N Engl J Med
– volume: 18
  start-page: 645
  year: 2019
  end-page: 658
  ident: r34
  article-title: Reference-based sensitivity analysis for time-to-event data.
  publication-title: Pharm Stat
– volume: 378
  start-page: 645
  year: 2018
  end-page: 657
  ident: r1
  article-title: Metastatic prostate cancer.
  publication-title: N Engl J Med
– volume: 61
  start-page: 857
  year: 2020
  end-page: 865
  ident: r24
  article-title: Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer.
  publication-title: J Nucl Med
– volume: 213
  start-page: 275
  year: 2019
  end-page: 285
  ident: r20
  article-title: Radioligand therapy with Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
  publication-title: AJR Am J Roentgenol
– volume: 38
  start-page: 3763
  year: 2020
  end-page: 3772
  ident: r6
  article-title: Rucaparib in men with metastatic castration-resistant prostate cancer harboring a or gene alteration.
  publication-title: J Clin Oncol
– volume: 34
  start-page: 1402
  year: 2016
  end-page: 1418
  ident: r29
  article-title: Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3.
  publication-title: J Clin Oncol
– volume: 76
  start-page: 469
  year: 2019
  end-page: 478
  ident: r14
  article-title: Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer.
  publication-title: Eur Urol
– volume: 19
  start-page: 825
  year: 2018
  end-page: 833
  ident: r23
  article-title: [ Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
  publication-title: Lancet Oncol
– volume: 382
  start-page: 2091
  year: 2020
  end-page: 2102
  ident: r3
  article-title: Olaparib for metastatic castration-resistant prostate cancer.
  publication-title: N Engl J Med
– volume: 71
  start-page: 281
  year: 2011
  end-page: 288
  ident: r12
  article-title: High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
  publication-title: Prostate
– volume: 60
  start-page: 517
  year: 2019
  end-page: 523
  ident: r17
  article-title: Dosimetry of Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes.
  publication-title: J Nucl Med
– volume: 58
  start-page: 85
  year: 2017
  end-page: 90
  ident: r19
  article-title: German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.
  publication-title: J Nucl Med
– volume: 44
  start-page: 1014
  year: 2017
  end-page: 1024
  ident: r27
  article-title: Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 82
  start-page: 2256
  year: 1998
  end-page: 2261
  ident: r11
  article-title: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
  publication-title: Cancer
– volume: 5
  start-page: 649
  year: 1982
  end-page: 655
  ident: r28
  article-title: Toxicity and response criteria of the Eastern Cooperative Oncology Group.
  publication-title: Am J Clin Oncol
– volume: 56
  start-page: 1697
  year: 2015
  end-page: 1705
  ident: r16
  article-title: The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions.
  publication-title: J Nucl Med
– volume: 75
  start-page: 88
  year: 2019
  end-page: 99
  ident: r2
  article-title: Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology.
  publication-title: Eur Urol
– volume: 45
  start-page: 228
  year: 2009
  end-page: 247
  ident: r31
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
  publication-title: Eur J Cancer
– volume: 53
  start-page: 227
  year: 1993
  end-page: 230
  ident: r8
  article-title: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
  publication-title: Cancer Res
– volume: 11
  start-page: 630589
  year: 2021
  end-page: 630589
  ident: r15
  article-title: Prostate-specific membrane antigen uptake and survival in metastatic castration-resistant prostate cancer.
  publication-title: Front Oncol
– volume: 38
  start-page: 395
  year: 2020
  end-page: 405
  ident: r5
  article-title: Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study.
  publication-title: J Clin Oncol
– volume: 7
  start-page: 199
  year: 2015
  end-page: 213
  ident: r33
  article-title: Comparison between two controlled multiple imputation methods for sensitivity analyses of time-to-event data with possibly informative censoring.
  publication-title: Stat Biopharm Res
– volume: 115
  start-page: 2934
  year: 2015
  end-page: 2974
  ident: r18
  article-title: Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications.
  publication-title: Chem Rev
– year: 1987
  ident: r32
  publication-title: Multiple comparison procedures ;John Wiley ;New York
– volume: 45
  start-page: 496
  year: 2018
  end-page: 508
  ident: r22
  article-title: Third-line treatment and Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 70
  start-page: 461
  year: 2019
  end-page: 477
  ident: r7
  article-title: Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications.
  publication-title: Annu Rev Med
– reference: 34936752 - N Engl J Med. 2021 Dec 23;385(26):2494-2495
– reference: 34936753 - N Engl J Med. 2021 Dec 23;385(26):2495
– reference: 34825836 - Radiol Imaging Cancer. 2021 Nov;3(6):e219026
– reference: 34331044 - Nat Rev Urol. 2021 Sep;18(9):510
– reference: 34312019 - Eur Urol. 2021 Oct;80(4):520-521
– reference: 34936751 - N Engl J Med. 2021 Dec 23;385(26):2494
– reference: 37032186 - Eur Urol. 2023 Jul;84(1):7-8
– reference: 34784728 - J Urol. 2022 Feb;207(2):467-469
– reference: 34262157 - Nat Rev Clin Oncol. 2021 Sep;18(9):542
SSID ssj0000149
Score 2.7460818
Snippet Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus...
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in...
AbstractBackgroundMetastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly...
SourceID proquest
pubmed
mms
SourceType Aggregation Database
Index Database
Publisher
StartPage 1091
SubjectTerms Adverse events
Aged
Aged, 80 and over
Androgen receptors
Androgens
Antigens
Biomarkers
Cancer therapies
Castration
Chemotherapy
Combined Modality Therapy
Computed tomography
Dipeptides - therapeutic use
Disease control
Drug dosages
Drug withdrawal
FDA approval
Gallium
Hematology
Heterocyclic Compounds, 1-Ring - therapeutic use
Humans
Immunotherapy
Kallikreins - antagonists & inhibitors
Lutetium - adverse effects
Lutetium - therapeutic use
Magnetic resonance imaging
Male
Medical prognosis
Metastases
Metastasis
Microenvironments
Middle Aged
Oncology
Pain
Patients
Positron-Emission Tomography
Prostate - diagnostic imaging
Prostate cancer
Prostate Disease
Prostate Disease General
Prostate-Specific Antigen - antagonists & inhibitors
Prostate-Specific Antigen - therapeutic use
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Prostatic Neoplasms, Castration-Resistant - radiotherapy
Quality of life
Radiation
Radioisotopes - adverse effects
Radioisotopes - therapeutic use
Radium
Survival Analysis
Treatments in Oncology
Urology
SubjectTermsDisplay Hematology/Oncology
Treatments in Oncology
Urology/Prostate Disease
Urology/Prostate Disease General
Title Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
URI https://nejm.org/doi/full/10.1056/NEJMoa2107322
https://www.ncbi.nlm.nih.gov/pubmed/34161051
https://www.proquest.com/docview/2572972853
https://www.proquest.com/docview/2544459208
Volume 385
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NasJAEB6qQuml9L-2VlLoNZjsJtnkVKwo0lYRW8Fb2E1WsGC0Gu99h75hn6Qzce3Pob0kkF0WMjPMfrOz8w3ADSJU6mCe2JGaCNvTUtoq5K7NIxmkioqLC_riXj_ojrz7sT82B24rc61y6xMLR53OEzojb6BpsUgw3F1uF682dY2i7KppoVGCClGXkVWLsfhBH2XgrzlBMhybuOc3qNP8XGK8Izj1zS3NZqu_MWax13QOYN-ARKu50eoh7OjsCHZ7Jg1-DA-P61zn0zW6NyE-3t4HT70mVeFZiECtns4llQlNE6slt6y49lCvCClmuTWgOg9EmDiKCl-ewKjTfm51bdMVwZ6xIMpxYeIIDFOXaZ-riKmI438kgXSZTDUFeBOMUULUjNCpo5Tna8fRAj8pzlJf8VMoZ_NMn4OVTIicMAySaJJ4PPVl4jsevohVXgnlVqGOcokz_TKLi2S1H8S_BFeF2lZksbH9VfytqSpcfw2j1VIqQmZ6vqY5nuf5EXPCKpxtRB0vNvQaMaeYC33Fxf-LX8Ieo_sl1M4hqEE5X671FQKEXNULK8Bn2HLrULlr9wfDT230uCs
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JSsRAEC1cQL2Iu-MaQY-NSXdnO4jIqIzORMQFvMXupAdGmIw6GcSb_-B_-FF-iVWZxOWgN0-BdOiQSlX1q66uVwDbiFCpg3nCQt32mTRKMR0Ih4lQeamm4uKCvjg68xrX8vTGvRmBt6oWho5VVj6xcNRpL6E98l1ULR76HFeX_fsHRl2jKLtatdAYqkXTPD9hyNbfOznE_7vD-fHRVb3Byq4CrMu9MGeOTxx7Qepw4wodch0KxZ3EUw5XqaEAqY0YP8Av801qay1dY9vGx1ta8NTVAucdhXEp0DSpMr3ufKOrKuF2uWNVcnoixtilzvY9fA9aFPXpHe12-79j2mJtO56B6RKUWgdDLZqFEZPNwURUpt3nodka5CbvDNCd-v77y-v5ZXRAVX8WIl4rMrmisqROYtVVxcLLLkyfkGmWW-dUV4KIFkdRwR4X4Ppf5LUIY1kvM8tgJW0iQwy8JGwnUqSuSlxb4oVY7LWvnRpsoFzizNx14yI57nrxD8HVYK0SWVzaWj_-0owabH0Oo5VQ6kNlpjegZ6SUbsjtoAZLQ1HH90M6j1hQjIe-aeXvyTdhsnEVteLWyVlzFaY4nW2hVhLeGozljwOzjuAk1xuFRlhw-98q-AFZQfG_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NSsNAEB5qheJF_LdaNYIelyab_4OIVIu1rRS10FvcTTZQoanaFPHmO_g2Po5P4kya-HPQm6dANmzI5Jvdb3d2vgE4QIZKFcxD5svYZZYSgknPNJjpCyeSlFycyRd3L53zvnUxsAcleCtyYehYZTEmZgN1NA5pj7yO0OK-y3F2qcf5sYjeafP4_oFRBSmKtBblNGYQaavnJ1y-TY5ap_ivDzlvnt00zlleYYCNuOOnzHBJb8-LDK5sU_pc-qbgRugIg4tI0WIpRr7v4Ve6KtKltGyl68rFW9LkkS1N7HcO5rEXj3zMaxjfpKty6p3vXuX6nsg36lTlfozvQe-imr1zo9Hkd36bzXPNJVjMCap2MkPUMpRUsgKVbh6CX4V2Z5qqdDjFodV1319ee9fdE8oA1JD9al2VCkpRGoZaQxSKvOxKTYilJqnWoxwTZLfYimB7XIP-v9hrHcrJOFGboIUxCSN6TujHoWVGtght3cILKdpLVxpV2EW7BIm6GwVZoNx2gh-Gq0KtMFmQ-90k-EJJFfY_m9FjKAwiEjWe0jOWZdk-170qbMxMHdzPpD0Ck9Z7OE5t_d35HlQQfEGnddnehgVOx1yoqoRTg3L6OFU7yFNSuZsBQoPb_0bgB4xG9fU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lutetium-177%E2%80%93PSMA-617+for+Metastatic+Castration-Resistant+Prostate+Cancer&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Sartor%2C+Oliver&rft.au=de+Bono%2C+Johann&rft.au=Chi%2C+Kim+N&rft.au=Fizazi%2C+Karim&rft.date=2021-09-16&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=385&rft.issue=12&rft.spage=1091&rft.epage=1103&rft_id=info:doi/10.1056%2FNEJMoa2107322&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon